ArticleFrontiers in pharmacology2025
Drug-associated infections and infestations in older adults with tumor necrosis factor-alpha inhibitors: a real-world retrospective and pharmacovigilance study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Infection-Related Adverse Events of Tisagenlecleucel in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: A FAERS Pharmacovigilance Study.Children (Basel, Switzerland) · 2026Article
- A Study on the Treatment of Rheumatoid Arthritis Using a Novel GelMA-HAMA Dual-Network Hydrogel Microneedle Loaded with MTX-NCs in Combination with Adalimumab.International journal of molecular sciences · 2026Article
- Astragaloside IV Modulates the Immune Response in Rheumatoid Arthritis and is Associated with Inhibition of the NAV2-Wnt/β-Catenin Signaling Cascade.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: One of the adverse events of greatest concern in patients receiving biologic therapies is the risk of infection, as infections are among the primary causes of premature mortality in this population, especially in the elderly. Because of the absence of head-to-head studies and limited duration and sample size of randomized controlled trials in the older adults, we analyzed the risk of infection associated with tumor necrosis factor (TNF) inhibitors by real-world adverse event analysis, seeking to identify medications with a reduced risk of infection and offering medication options for sensitive patients. Methods: A retrospective pharmacovigilance investigation was undertaken utilizing the FDA Adverse Event Reporting System (FAERS) database from the first quarter of 2010 to the fourth quarter of 2023. Drug-associated infections and infestations associated with TNF-α inhibitors (adalimumab, infliximab, etanercept, golimumab, and certolizumab pegol) were evaluated using a disproportionality analysis. The Reporting Odds Ratio (ROR) and Bayesian Confidence Propagation Neural Network (BCPNN) were utilized to detect AE signals. Results: A total case of 3,239,508 cases were included after removing duplicates. Among the protective signals, etanercept showed the lowest IC Conclusion: The research highlighted that the difference in the risk of infection in the elderly who used TNF-α inhibitors between various TNF-α inhibitors, adverse events and therapeutic indications, respectively. The use of TNF-α inhibitors increased the infection risk in older adults. Etanercept exhibited the lowest infection risk, whereas certolizumab pegol manifested the highest risk in infections and infestations. Doctors need to pay close attention to the appearance of mycobacterial infectious disorders in older adults treating with TNF-α inhibitors, which displayed the strongest signal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.